CA 2024 * | 529 M 494 M | CA 2025 * | 681 M 636 M | Capitalisation | 3,04 Md 2,84 Md |
---|---|---|---|---|---|
Résultat net 2024 * | -1 M -934 k | Résultat net 2025 * | 120 M 112 M | VE / CA 2024 * | 6,02 x |
Dette nette 2024 * | 139 M 130 M | Dette nette 2025 * | 24,31 M 22,71 M | VE / CA 2025 * | 4,51 x |
PER 2024 * |
-1 694
x | PER 2025 * |
26,5
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 89,81 % |
Dernier transcript sur Amicus Therapeutics
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 01/04/06 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 21/08/23 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 01/07/22 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 01/04/06 |
Lynn Bleil
BRD | Director/Board Member | 60 | 11/09/18 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 27/06/19 |
Varia. 1 janv. | Capi. | |
---|---|---|
+1,51 % | 42,75 Md | |
+49,22 % | 41,61 Md | |
+8,57 % | 41,34 Md | |
-12,36 % | 26,59 Md | |
+8,92 % | 25,49 Md | |
-25,13 % | 18,12 Md | |
+29,17 % | 12,24 Md | |
-3,12 % | 11,76 Md | |
+6,35 % | 11 Md |